CN101491574A - Traditional Chinese medicine compound recipe for treating chronic hepatitis-B and preparation method thereof - Google Patents
Traditional Chinese medicine compound recipe for treating chronic hepatitis-B and preparation method thereof Download PDFInfo
- Publication number
- CN101491574A CN101491574A CNA2008100566521A CN200810056652A CN101491574A CN 101491574 A CN101491574 A CN 101491574A CN A2008100566521 A CNA2008100566521 A CN A2008100566521A CN 200810056652 A CN200810056652 A CN 200810056652A CN 101491574 A CN101491574 A CN 101491574A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine compound
- preparation
- serissa foetida
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicine compound prescription for treating chronic hepatitis B and a method for preparing the same. The Chinese medicine compound prescription consists of mile swertia, serissa foetida comm, astragalus root and radix salivae miltiorrhizae; the materials are decocted by water and extract to obtain a compound active extract. The Chinese medicine compound prescription has the protecting function on liver injury, can reduce the level of ALT and MDA of serum in liver, raise the activity of SOD of serum and has effect of treating hepatitis caused by bcg vaccine. The Chinese medicine compound prescription can be used for preparing a drug with the function of treating chronic hepatitis B.
Description
Technical field
Preparation technique field in the invention belongs to is specifically related to a kind of compound Chinese medicinal preparation for the treatment of chronic hepatitis B and preparation method thereof.
Background technology
The current whole world has 2,000,000,000 people to suffer the invasion and attack of hepatitis B virus (HBV) approximately, and 3.5 hundred million person-times of persons that develop into the chronic HBV infection are wherein arranged.Chronic hepatitis B can develop into liver cirrhosis and hepatocarcinoma, and the whole world is annual to have 1,000,000 people to die from the relevant disease of HBV infection approximately.China is the high region of disease of hepatitis B, has 50% people to infect HBV approximately, and the Chronic HBV carrier accounts for 9.75% of national population.Current, the antiviral drugs that is used for the treatment of hepatitis B both at home and abroad mainly contains interferon and lamivudine, but is easy to generate drug resistance.Therefore, it is very necessary that safe, effective, stable medicine has seemed, and Chinese medicine has its unique curative effect in this respect.
Summary of the invention
The object of the present invention is to provide that a kind of compatibility is reasonable, curative effect is good, the Chinese medicine compound of the treatment chronic hepatitis B that has no side effect.
Chinese medicine compound of the present invention is made up of following bulk drugs: Herba Swertiae Mileensis, Serissa foetida, the Radix Astragali and Radix Salviae Miltiorrhizae.
Among the present invention, with Herba Swertiae Mileensis and soothing the liverly to let out wet Serissa foetida be principal agent with liver heat removing function of gallbladder promoting, the effect of damp eliminating jaundice eliminating, be aided with have invigorating the spleen and replenishing QI, the Radix Salviae Miltiorrhizae of the Radix Astragali of consolidating superficial resistance and inducing diuresis and blood circulation promoting and blood stasis dispelling effect, can effectively treat chronic hepatitis B.
Among the present invention, the weight proportion relation of each principal agent is: Herba Swertiae Mileensis 8-15 part, Serissa foetida 7-12 part, Radix Astragali 4-10 part, Radix Salviae Miltiorrhizae 4-10 part, preferably, Herba Swertiae Mileensis 9-13 part, Serissa foetida 8-11 part, Radix Astragali 5-8 part, Radix Salviae Miltiorrhizae 5-8 part, more preferably Herba Swertiae Mileensis is 10 parts, 8 parts of Serissa foetida, 8 parts of the Radixs Astragali, 6 parts of Radix Salviae Miltiorrhizaes.
Another object of the present invention is to provide a kind of method for preparing Chinese medicine compound active component of the present invention.
The preparation method of active component of the present invention can realize in the following way: take by weighing Herba Swertiae Mileensis, Serissa foetida, the Radix Astragali, Radix Salviae Miltiorrhizae by weight, pulverize, merging decocts with 10 times of water gagings and extracts 3 times, and extraction time is 2 hours, 1.5 hours, 1.5 hour, filter, merging filtrate, filtrate decompression concentrates, vacuum or spray drying get active component extract.
Perhaps, the preparation of active component of the present invention also can prepare in the following way: get Serissa foetida, the alcohol reflux twice with 80% filters, and merging filtrate, concentrating under reduced pressure become the extractum shape; Serissa foetida medicinal residues and Herba Swertiae Mileensis, the Radix Astragali, Radix Salviae Miltiorrhizae are merged, add 10 times of water gagings and decoct and extract 3 times, filter, merging filtrate, concentrating under reduced pressure become the extractum shape, the extractum of two parts gained is merged, vacuum or spray drying, active component extract.
With Chinese medicine compound of the present invention is main active, adds acceptable auxiliary in the suitable pharmacy, can be made into the preparation of various forms for oral administration.Described oral Preparation can be to be the unitary Peroral solid dosage form drug-delivery preparation of administration with tablet, capsule or pill etc., also can be to be the unitary liquid oral drug-delivery preparation of administration with oral liquid etc.Acceptable auxiliary or excipient in the pharmacy that adds can be filleies, as lactose, dextrin, microcrystalline cellulose, starch etc.; Disintegrating agent such as polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium etc., binding agent such as starch slurry, starch slurry sodium, hypromellose, polyvidone etc., surfactant such as dodecyl sodium sulfate, lubricant such as magnesium stearate, Pulvis Talci, Polyethylene Glycol etc. can also have suspending agent, cosolvent, antiseptic etc.
Chinese medicine compound of the present invention has the effect of treatment chronic hepatitis B, can be used for preparing the medicine with treatment and the effect of prevention chronic hepatitis B.
Chinese medicine compound of the present invention is to the long term toxicity test of rat
Experimental technique: the rat dosage is respectively 120g/kg, 60g/kg and 30g/kg, and part is not equivalent to recommend 66,33 and 16.7 times of clinical consumption, continuous irrigation stomach 3 months.
Experimental result: Chinese medicine compound of the present invention during whole test in the slight rat body weight that promotes increase, general state, routine blood test and the hepatic and renal function etc. of rat are not all had significantly infringement, the weight and the tissue morphology of each main organs do not had significant toxic action yet.Heavy dose of long term administration does not have tangible chronic toxicity infringement to rat.
The Pharmacodynamic test of active extract result of Chinese medicine compound of the present invention
1, to CCl
4Due to the protective effect of acute and chronic hepatic injury
Experimental technique
Acute liver damage: 40 mices are divided into matched group, CCl at random
4Model group, Chinese medicine compound high and low dose group of the present invention (20g crude drug, 10g crude drug/sky), 10 every group.Behind the laboratory rearing 2 days, except that matched group and model group mice usefulness distilled water 0.5ml/ Mus filling stomach, all the other each groups are all according to dosage irritated stomach, and 1 time/day, continuous 1 week.2h after the last administration is except that control group mice, all by 10ml/kg disposable celiac injection 0.1%CCl
4The Oleum Arachidis hypogaeae semen solvent, water is can't help in fasting, and the 16h posterior orbit is got blood, centrifuging and taking serum.
Chronic hepatic injury: 40 mices are divided into 4 groups at random, 10 every group.Medication is tested processing method with acute liver damage.Laboratory rearing after 2 days except that matched group is injected isopyknic Oleum Arachidis hypogaeae semen, all with 5ml/kg subcutaneous injection 20%CCl
4The Oleum Arachidis hypogaeae semen solvent, injection in per 5 days 1 time is injected 6 times altogether, gives Drug therapy simultaneously, weighed 1 time in per 5 days, along with the increase of mice body weight, the also corresponding increase of dosage.After the medication the 42nd day, eye socket is got blood, centrifuging and taking serum.
Experimental result: Chinese medicine compound of the present invention is to by CCl
4Due to acute and chronic hepatic injury all have protective effect, can significantly reduce serum glutamic pyruvic transminase (ALT), malonaldehyde (MDA) content, superoxide dismutase (SOD) level in the serum is raise.
2, to the protective effect of chemical liver injury mice
Experimental technique: 40 of mices are divided into 4 groups at random, and 10 every group, continuous 7 days oral administrations, the aminogalactose of 1 hour lumbar injection 800mg/kg after the last administration is got hematometry blood literization index every 16 hours posterior orbits: ALT, MDA.
Experimental result: Chinese medicine compound of the present invention can obviously reduce the content of the ALT of aminogalactose mice, and high dose group can significantly reduce the MDA level of model group.
3, bacillus calmette-guerin vaccine is caused the effect of mouse immune hepatitis
Experimental technique: 40 of mices are divided into 4 groups at random, and 10 every group, i.e. normal control group, model group, Chinese medicine compound high and low dose administration group of the present invention.Except that the normal control group, all the other all at administration tail vein injection the previous day bacillus calmette-guerin vaccine 0.75mg/ only respectively organize mice, and successive administration is (0.2ml/10g) after 12 days, and tail vein injection lipopolysaccharide 7.5ug/ only.1 as a child won eyeball gets blood survey ALT, gets liver and weighs, and calculates the liver coefficient.
Result of the test: Chinese medicine compound high and low dose group of the present invention all can reduce the blood ALT of bacillus calmette-guerin vaccine mouse immune hepatitis model, has the effect of treatment bacillus calmette-guerin vaccine mouse immune hepatitis.
Specific embodiment
Embodiment 1
10 parts of Herba Swertiae Mileensises, 8 parts of Serissa foetida, 8 parts of the Radixs Astragali, 6 parts of Radix Salviae Miltiorrhizaes are pulverized, and mix, with water boiling and extraction three times, each solvent load is 10 times, 8 times, 8 times, 2 hours extraction times, 1 hour, 1 hour, filters merging filtrate, filtrate decompression concentrates, and spray drying gets activity extract.
Embodiment 2
15 parts of Herba Swertiae Mileensises, 10 parts of Serissa foetida, 10 parts of the Radixs Astragali, 8 parts of Radix Salviae Miltiorrhizaes are pulverized, and mix, with water boiling and extraction three times, each solvent load is 12 times, 8 times, 8 times, 2 hours extraction times, 1 hour, 1 hour, filters merging filtrate, filtrate decompression concentrates, and spray drying gets activity extract.
Embodiment 3
8 parts of Herba Swertiae Mileensises, 7 parts of Serissa foetida, 4 parts of the Radixs Astragali, 4 parts of Radix Salviae Miltiorrhizaes are pulverized, and mix, with water boiling and extraction three times, each solvent load is 10 times, 8 times, 8 times, 2 hours extraction times, 1.5 hours, 1.5 hours, filters merging filtrate, filtrate decompression concentrates, and spray drying gets activity extract.
Embodiment 4
10 parts of Herba Swertiae Mileensises, 10 parts of Serissa foetida, 10 parts of the Radixs Astragali, 10 parts of Radix Salviae Miltiorrhizaes are pulverized, and mix, with water boiling and extraction three times, each solvent load is 10 times, 8 times, 8 times, 2 hours extraction times, 1 hour, 1 hour, filters merging filtrate, filtrate decompression concentrates, and spray drying gets activity extract.
Embodiment 5
12 parts of Herba Swertiae Mileensises, 10 parts of Serissa foetida, 7 parts of the Radixs Astragali, 6 parts of Radix Salviae Miltiorrhizaes, Serissa foetida are with 80% alcohol reflux 2 times, and each solvent load is 10 times, 10 times, filter, merging filtrate, filtrate decompression is condensed into extractum, Serissa foetida extractum; The Serissa foetida medicinal residues mix with Herba Swertiae Mileensis, the Radix Astragali, Radix Salviae Miltiorrhizae, with water boiling and extraction three times, each solvent load is 10 times, 10 times, 10 times, 2 hours extraction times, 1.5 hours, 1 hour, filter merging filtrate, after filtrate decompression concentrates, with Serissa foetida extractum mix homogeneously, vacuum drying, get activity extract.
Claims (10)
1, a kind of Chinese medicine compound for the treatment of chronic hepatitis B is characterized in that being made up of following bulk drugs: Herba Swertiae Mileensis, Serissa foetida, the Radix Astragali, Radix Salviae Miltiorrhizae.
2, Chinese medicine compound as claimed in claim 1 is characterized in that the weight proportion of described crude drug is: Herba Swertiae Mileensis 8-15 part, Serissa foetida 7-12 part, Radix Astragali 4-10 part, Radix Salviae Miltiorrhizae 4-10 part.
3, Chinese medicine compound as claimed in claim 1 is characterized in that the preferred weight proportioning of described crude drug is: Herba Swertiae Mileensis 9-13 part, Serissa foetida 8-11 part, Radix Astragali 5-8 part, Radix Salviae Miltiorrhizae 5-8 part.
4, Chinese medicine compound as claimed in claim 1 is characterized in that the more preferably weight proportion of described crude drug is: 10 parts of Herba Swertiae Mileensises, 8 parts of Serissa foetida, 8 parts of the Radixs Astragali, 6 parts of Radix Salviae Miltiorrhizaes.
5, as Chinese medicine compound as described in arbitrary claim in the claim 1 to 4, it is characterized in that except that the primary raw material medicine, also contain acceptable excipient in the pharmacy.
6, a kind of preparation is as the method for the described Chinese medicine compound active component of arbitrary claim in the claim 1 to 4, it is characterized in that getting Herba Swertiae Mileensis, Serissa foetida, the Radix Astragali, Radix Salviae Miltiorrhizae, be ground into coarse powder, merge, with water boiling and extraction, filter, merge water boiling and extraction liquid, concentrating under reduced pressure, drying, pulverize, get active component.
7, a kind of preparation is as the method for Chinese medicine compound active component as described in arbitrary claim in the claim 1 to 4, and it is characterized in that: get Serissa foetida, the alcohol reflux with 80% 2 times filters, and filtrate decompression concentrates, Serissa foetida concentrated solution I; Serissa foetida medical material behind 80% ethanol extraction and Herba Swertiae Mileensis, the Radix Astragali, Radix Salviae Miltiorrhizae are merged, decoct with water extraction, filter, get filtrate, concentrating under reduced pressure gets concentrate II; Merge concentrate I, II, mixing, drying gets active component.
8, a kind of is the preparation of main active with the described Chinese medicine compound of arbitrary claim in the claim 1 to 4, it is characterized in that being mainly oral formulations.
9, preparation as claimed in claim 8 is characterized in that described oral formulations is for being the unitary preparation of administration with tablet form, Capsule form or drink form.
10, has application in the treatment chronic hepatitis B medicine as Chinese medicine compound as described in arbitrary claim in the claim 1 to 4 in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100566521A CN101491574A (en) | 2008-01-23 | 2008-01-23 | Traditional Chinese medicine compound recipe for treating chronic hepatitis-B and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100566521A CN101491574A (en) | 2008-01-23 | 2008-01-23 | Traditional Chinese medicine compound recipe for treating chronic hepatitis-B and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101491574A true CN101491574A (en) | 2009-07-29 |
Family
ID=40922475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100566521A Pending CN101491574A (en) | 2008-01-23 | 2008-01-23 | Traditional Chinese medicine compound recipe for treating chronic hepatitis-B and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101491574A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103859505A (en) * | 2014-03-31 | 2014-06-18 | 哈尔滨升益生物科技开发有限公司 | Serissa serissoide soup capable of soothing liver and promoting blood circulation and production method thereof |
| CN105748652A (en) * | 2016-04-01 | 2016-07-13 | 武汉理工大学 | Herba serissae japonicae capsules for treating gout and preparation method thereof |
-
2008
- 2008-01-23 CN CNA2008100566521A patent/CN101491574A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103859505A (en) * | 2014-03-31 | 2014-06-18 | 哈尔滨升益生物科技开发有限公司 | Serissa serissoide soup capable of soothing liver and promoting blood circulation and production method thereof |
| CN105748652A (en) * | 2016-04-01 | 2016-07-13 | 武汉理工大学 | Herba serissae japonicae capsules for treating gout and preparation method thereof |
| CN105748652B (en) * | 2016-04-01 | 2020-04-21 | 武汉理工大学 | Serissa japonica capsule for treating gout and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100384467C (en) | Traditional Chinese medicine composition for treating hepatitis and fatty liver | |
| CN102058673A (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN104225466A (en) | Traditional Chinese medicinal composition used for lowering blood lipid | |
| CN103933195B (en) | A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine | |
| CN101491574A (en) | Traditional Chinese medicine compound recipe for treating chronic hepatitis-B and preparation method thereof | |
| CN100518813C (en) | Composite medicine for treating hepatopathy and its preparing process | |
| CN102743460A (en) | Chinese medicine preparation for treating hepatopathy and preparation method | |
| CN101390970A (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN1795901B (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN105477465A (en) | Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation | |
| CN101618156A (en) | Medicine composition for treating hepatitis B and preparation method thereof | |
| CN104547070A (en) | Medical composition resistant to hepatitis b viruses as well as preparation method and application of medical composition | |
| CN101057906B (en) | Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application | |
| CN103519185A (en) | Health care product for preventing and treating chemical liver injury | |
| CN103341117A (en) | Composition for treating hepatitis B and preparation method and usage thereof | |
| CN102068658B (en) | Chinese medicine composite for clearing heat, detoxicating, dispelling dampness and eliminating stagnation and preparation method thereof | |
| CN101352484B (en) | Medicament composition for treating acute and chronic hepatitis | |
| CN103830563B (en) | The Chinese medicine composition of preventing and treating chronic hepatitis C and application thereof | |
| CN100591353C (en) | Traditional Chinese medicine formulation for treating hepatitis and its preparation method | |
| CN105853768A (en) | Traditional Chinese medicine formula for treating rheumatoid arthritis and preparing method and application thereof | |
| CN100356975C (en) | Medicinal composition for treating chronic hepatitis and its preparing method | |
| CN101264299A (en) | Medicine for treating chronic hepatitis B and preparation thereof | |
| CN103550680A (en) | Traditional Chinese medicine prescription for treating hyperbilirubinemia caused skin itch and preparation method thereof | |
| CN104510857A (en) | Traditional Chinese medicinal effective part composition for lowering lipid and preparations of traditional Chinese medicinal effective part composition | |
| CN103505500A (en) | Traditional Chinese medicine composition for treating hepatitis B and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090729 |